Pharmasurgics to begin Phase II Clinical Trial for Prevention of Post-Surgical Adhesions
|
|
Pharmasurgics AB – part of the Karolinska Development dermatology and wound healing company "Pergamum" – today announced that Pharmasurgics has received approval from the Swedish Medical Products Agency to begin a Phase II clinical trial. The trial will begin in December 2009 and will monitor the safety and efficacy of PharmaSurgics' novel candidate drug for the prevention of post-surgical adhesions in patients undergoing hand surgery.
|
|
More
|
|
Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
|
|
DermaGen AB today announced that it has received promising results from a clinical Phase I/IIa study. DermaGen AB is developing a novel antimicrobial peptide (AMP) treatment for atopic dermatitis. Atopic dermatitis is a chronic inflammatory skin disease where dry skin and the skin’s weakened barrier function make patients susceptible to colonization by microorganisms, a triggering or exacerbating factor of the disease
|
|
More
|
Pergamum appoints Jørgen Thorball as New Chairman of the Board
|
|
Karolinska Development AB and Pergamum AB announced today the appointment of Jørgen Thorball as Chairman of the Board of Directors of Pergamum AB, as of November 25, 2009. Dr. Thorball has extensive experience including the successful development and commercialization of new products within the pharmaceutical and healthcare industries.
|
|
More
|
Pergamum attends Rodman & Renshaw Conference
|
|
Pergamum CEO Magnus Precht will present Pergamum at the Rodman & Renshaw Annual Global Investment Conference in New York September 9-11, 2009 and will be available for one-on-one meetings with investors and potential partners during the conference.
|
|
More
|
DermaGen completes patient enrolment for Phase I/IIa clinical trial
|
|
DermaGen AB has completed patient enrolment for a Phase I/IIa clinical trial for DPK‐
060, a novel antimicrobial peptide.
The study is composed of two parts; an open safety and local tolerability part and a 1:1
randomized, double‐blind efficacy part comparing DPK‐060 treatment against a placebo.
The study encompasses patients with atopic dermatitis and initial analysis of patient
data has already begun.
The primary endpoint of the study is to measure the reduction of microbes in the
treated eczemas after DPK‐060 therapy compared with placebo treatment. Secondary
clinical endpoints in the study include documentation of clinical score of the eczema
during and after treatment, safety and local tolerability.
The results from the study are expected to be released in Q3 of 2009.
For more information about DermaGen AB please visit www.dermagen.se
Or contact:
Dr. Jan Alenfall, CEO
Phn: + 46 (0)46 192 197
Mob: + 46 (0)709 315 115
E‐mail:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
|
|
|
|
|
